Bladder Cancer Coverage from Every Angle

Ramucirumab Plus Docetaxel in Urothelial Carcinoma: Patient-Reported Outcomes From RANGE Trial

By: Joshua D. Madera, MS
Posted: Tuesday, January 19, 2021

For patients with platinum-refractory advanced urothelial carcinoma, treatment with the monoclonal-antibody ramucirumab plus docetaxel did not appear to negatively impact the quality of life as compared with docetaxel alone, according to the randomized, phase III RANGE trial, published in BMC Urology. Also, patients reported an improved time to deterioration and tumor-associated pain with ramucirumab treatment, explained Thomas Powles, MBBS, MRCP, MD, of the Barts Cancer Centre, London, United Kingdom, and colleagues.

“The association of pain palliation with tumor response and disease control observed in this study may be used when considering therapeutic choices for advanced urothelial carcinoma,” the investigators commented.

A total of 530 patients with platinum-refractory advanced urothelial carcinoma were recruited for this double-blind, randomized study. Patients were stratified and received one of two treatment regimens every 21 days until disease progression or excessive toxicity: 10 mg/kg of ramucirumab plus 75 mg/m2 of docetaxel or a placebo plus 75 mg/m2 of docetaxel. All patients were administered the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire C30 (EORTC QLQ-C30) and EuroQoL five-dimensions (EQ-5D-5L) at baseline, at the beginning of each treatment cycle, and 30 days post final therapy.

At baseline assessment, results from the EORTC QLQ-C30 were similar in both treatment groups. Both groups reported increased impairment in aspects of quality of life, fatigue, insomnia, and pain. However, following a therapeutic intervention, data from the EORTC QLQ-C30 revealed a significant improvement in pain perception for patients treated with ramucirumab. Post-treatment, both groups still experienced similar perceptions of fatigue, quality of life, and insomnia. Moreover, the time to deterioration was improved in patients treated with ramucirumab compared with patients who received the placebo. Furthermore, although the EQ-5D-5L questionnaire's baseline assessment did not reveal any disparities between treatment groups, the post-intervention assessment revealed worsening scores at a follow-up visit after treatment discontinuation.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.